NDAORALSUSPENSION, EXTENDED RELEASE
Approved
May 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
ONYDA XR (clonidine hydrochloride) by Teva is 2 -adrenergic receptors in the brain. Approved for ocular redness. First approved in 2024.
Drug data last refreshed 20h ago
Mechanism of Action
2 -adrenergic receptors in the brain. Clonidine is not a central nervous system stimulant. The mechanism of action of clonidine in ADHD is not known.
Indications (1)
Company
Worked on ONYDA XR at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.